Tarsus Pharmaceuticals, Inc. TARS Net Operating Loss Carryforwards
Net Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLossCarryforwards.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s net operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s net operating loss carryforwards?
- Tarsus Pharmaceuticals, Inc. (TARS) reported net operating loss carryforwards of $176.1M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s net operating loss carryforwards changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s net operating loss carryforwards increased by 27.1% year-over-year, from $138.5M to $176.1M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s net operating loss carryforwards?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s net operating loss carryforwards has grown at a 47.4% compound annual growth rate (CAGR), from $25.3M to $176.1M.
- What does net operating loss carryforwards mean?
- These are tax assets representing losses that can be used to reduce taxable income in future periods. They provide a potential future tax shield, improving cash flow by lowering future tax payments. Investors monitor these to estimate the duration and magnitude of potential tax savings.